Who
Laura Shawver
Director
Company insider
Files Form 4 as: Chief Executive Officer, ARS Pharmaceuticals; Director, Relay Therapeutics; Director, Nkarta; President and CEO, Synthorx; Director, Cornerstone Therapeutics.
In numbers
- Trades disclosed
- 120
- Buys
- 0
- Sells
- 22
- Bought
- $0
- Sold
- $8.6M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 6 Jun 2012
- Last trade
- 24 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 26 Jun 2026 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 25 Jun 2025filed 27 Jun 2025 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 7 Apr 2025filed 8 Apr 2025 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —22,509 at $0.00 | filing |
| 7 Apr 2025filed 8 Apr 2025 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —27,493 at $0.00 | filing |
| 7 Apr 2025filed 8 Apr 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $109K22,509 at $4.85 | filing |
| 7 Apr 2025filed 8 Apr 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $133K27,493 at $4.85 | filing |
| 7 Apr 2025filed 8 Apr 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $615K50,002 at $12.30 | filing |
| 6 Mar 2025filed 7 Mar 2025 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —49,600 at $0.00 | filing |
| 6 Mar 2025filed 7 Mar 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $241K49,600 at $4.85 | filing |
| 6 Mar 2025filed 7 Mar 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $556K49,600 at $11.21 | filing |
| 5 Mar 2025filed 7 Mar 2025 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —400 at $0.00 | filing |
| 5 Mar 2025filed 7 Mar 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $1,940400 at $4.85 | filing |
| 5 Mar 2025filed 7 Mar 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $4,400400 at $11.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —9,064 at $0.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —40,936 at $0.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $29K9,064 at $3.15 | filing |
| 3 Feb 2025filed 4 Feb 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $199K40,936 at $4.85 | filing |
| 3 Feb 2025filed 4 Feb 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $616K50,000 at $12.31 | filing |
| 6 Jan 2025filed 7 Jan 2025 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
News
Contrasting ARS Pharmaceuticals (NASDAQ:SPRY) and Theravance Biopharma (NASDAQ:TBPH)SPRY · dailypolitical.com · 21 Oct 2026
0 headlines in the last 90 days name Laura Shawver; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.